Antifungal Resistance Trends of Candida auris Clinical Isolates, New York-New Jersey, 2016-2020

  15 January 2022

About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to <1% for New York C. auris clinical isolates but not for New Jersey, highlighting the regional differences.

Author(s): Shannon Kilburn, MPH, Gabriel Innes, VDM, PhD, Monica Quinn, MS, Karen Southwick, MD, Belinda Ostrowsky, MD, Jane A. Greenko, MPH, Emily Lutterloh, MD, MPH, Rebecca Greeley, MPH, Reed Magleby, MD, MS, Vishnu Chaturvedi, PhD, Sudha Chaturvedi, PhD
Effective Surveillance  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!